Figure 3

Effect of ERβ on HER2 and HER3 protein and mRNA expression. (A) T47-DERβ cells were treated for 4 or 7 days with 10 ng/mL (-ERβ) or 0.01 ng/mL (+ERβ) doxycycline in the presence or absence of 10 nM DPN with or without 100 nM ICI or 100 nM (4-OH-T), and lysates were analyzed by immunoblotting. Also, cells were analyzed for HER2 mRNA expression by performing quantitative polymerase chain reactions (qPCRs). (B) T47-DERβ cells were treated for 4 days with 10 ng/mL (-ERβ) or 0.01 ng/mL (+ERβ) doxycycline in the presence or absence of 10 nM DPN with or without 100 nM ICI or 100 nM 4-OH-T, and lysates were analyzed by immunoblotting. Also, cells were analyzed for HER3 mRNA expression by performing qPCR. Significant differences were analyzed using one-way analysis of variance (ANOVA) and Tukey's multiple posttest: *P < 0.05 vs. -ERβ, ^aP < 0.05 vs. -ERβ + DPN, ^bP < 0.05 vs. -ERβ + DPN + ICI, ^cP < 0.05 vs. -ERβ + 4-OH-T, ^dP < 0.05 vs. -ERβ + ICI, ^eP < 0.05 vs. -ERβ + DPN + 4-OH-T.